Artesunate/amodiaquine
Malaria drug
From Wikipedia, the free encyclopedia
Artesunate/amodiaquine, sold under the trade name Camoquin among others, is a medication used for the treatment of malaria.[2][3] It is a fixed-dose combination of artesunate and amodiaquine.[2] Specifically it recommended for acute uncomplicated Plasmodium falciparum malaria.[4] It is taken by mouth.[3]
| Combination of | |
|---|---|
| Artesunate | Antimalarial |
| Amodiaquine | Antimalarial |
| Clinical data | |
| Trade names | Camoquin, others[1] |
| Other names | ASAQ |
| ATC code | |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
  (what is this?) (verify) | |
Common side effects include loss of appetite, nausea, abdominal pain, sleepiness, trouble sleeping, and cough.[5] Safety in pregnancy is not clear; however, the medication may be used if others are not possible.[5] It is believed to be safe for use during breastfeeding.[5] Artesunate and amodiaquine are both antimalarial medication; however, work by different mechanisms.[5]
Artesunate/amodiaquine was commercially launched in 2007.[6] It is on the World Health Organization's List of Essential Medicines.[2] Artesunate/amodiaquine is available as a generic medication.[6] As of 2014 it is not commercially available in the United States or United Kingdom.[1][7]
Medical uses
Early clinical trials showed that a once-a-day dosage was effective.[8] It was subsequently clinically shown to be equally effective as artemether/lumefantrine,[9] although it is likely to be more effective in the field due to its simpler once-a-day dosage compared to artemether/lumefantrine twice-per-day dosage.
Society and culture
Artesunate/amodiaquine was commercially launched in 2007 as an affordable treatment for malaria, devised by DNDi in partnership with Sanofi-Aventis.[6] ASAQ was handed over to the MMV Access and Product Management Team in May 2015.[10]
